Infectivity of hepatic allografts with antibodies to hepatitis B virus

Transplantation

Volumn 64, Issue 11, 1997, Pages 1582-1584

  Dodson, S Forrest ^a,c   Issa, Samir ^a   Araya, Victor ^a   Gayowski, Timothy ^a   Pinna, Antonio ^a   Eghtesad, Bijan ^b   Iwatsuki, Shunzaboro ^a   Montalvo, Eduardo ^a   Rakela, Jorge ^a   Fung, John J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY;

ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INFECTIVITY;

HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER TRANSPLANTATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0031456043     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199712150-00013     Document Type: Article

References (10)

1. Chazouilleres O, Mamish D, Kim M, et al. "Occult" hepatitis B virus as a source of infection in liver transplant recipients. Lancet 1994; 343: 142.
2. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230.
3. Douglas D, Rakela J, Wright T, et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transplant Surg 1997; 3: 105.
4. Douglas D, Rakela J, Taswell H, et al. Hepatitis B virus replication patterns after orthotopic liver transplantation: de novo versus recurrent infection. Transplant Proc 1993; 25: 1755.
5. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 842.
6. Grellier L, Brown D, McPhilips P, et al. Lamivudine prophylaxis: a new strategy for prevention of reinfection in liver transplantation for hepatitis B DNA positive cirrhosis [Abstract]. Hepatology 1995; 22: 224A.
7. Gutfreund K, Fischer K, Tipples G, et al. Lamivudine results in a complete and sustained suppression of hepatitis B virus replication in patients requiring orthotopic liver transplantation for cirrhosis secondary to hepatitis B [Abstract]. Hepatology 1995; 22: 328A.
8. Van Thiel D, El-Ashmawy L, Love L, et al. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992; 37: 1245.
9. Iwarson S, Tabor E, Thomas HC, Snoy P, Gerety RJ. Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology 1985; 88(3): 763.
10. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. J Hepatol 1995; 23: 14.